Astex
  • Discover Astex
    • Our Mission & Values
    • Our Leadership Team
      • UK – Discovery Research
        • Jeremy Carmichael
        • Gianni Chessari
        • Harren Jhoti
        • Michelle Jones
        • Neil Jones
        • John Lyons
        • Chris Murray
        • Marc O’Reilly
        • David Rees
        • Nicola Wallis
        • Nicola Wilsher
      • USA – Product Development
        • Martin Buckland
        • Harold N. Keer
        • Nipun Davar
        • Beloo Mirakhur
        • Talat Ashraf
        • D. Jeffery Grimes
        • Joseph Iovino
        • Samuel Jason
        • Daisy Leung
        • Aram Oganesian
        • Pratibha Sampeur
        • Sonia Souza
        • Nancy Worrell
    • Our History
    • Corporate Social Responsibility
  • R&D
    • Clinical Pipeline
      • Proprietary Products and Programs
        • Oral Decitabine and Cedazuridine (ASTX727) (Hematological Malignancies)
        • Tolinapant (ASTX660) – Solid Tumors & Lymphomas
        • ASTX029 Extracellular Signal-Related Protein Kinases (ERK 1/2) Inhibitor (Solid Tumors)
        • ASTX295 Oral Murine Double Minute 2 (MDM2) antagonist (Solid Tumors)
        • Azacitidine and Cedazuridine (ASTX030) Oral DNMT inhibitor (Hematological Malignancies)
        • TAS1440 Oral LSD1 inhibitor (Hematological Malignancies)
        • TAS1553 Oral small molecule ribonucleotide reductase (RNR) inhibitor (Hematological Malignancies)
      • Partnered Products and Programs
        • Kisqali® (ribociclib) CDK4/6 inhibitor (Oncology)
        • Balversa® (erdafitinib) FGFr inhibitor (Oncology)
        • Truqap™ PKB/Akt Inhibitor (Oncology)
        • Multiple Targets and Therapeutic Areas
    • Pyramid™ Discovery Platform
    • Oncology and CNS Discovery
    • Sustaining Innovation Postdocs
  • Partnering
  • Our People & Culture
    • Career Opportunities
  • Media
    • Press Releases
    • Conferences & Meetings
    • Presentations & Publications
    • Interactive Scientific Resources
      • Interactive Software
    • Astex in the News
  • Contact
  • Search
  • Menu Menu
You are here: Home1 / 20082 / SuperGen’s MP-470 Sensitizes Prostate and Breast Cancer Cells to...

SuperGen’s MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib

14 April 2008/in 2008, News

SuperGen’s MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib

Share this entry
  • Share on Twitter
https://astx.com/wp-content/uploads/2019/11/logo_white.png 0 0 webadmin https://astx.com/wp-content/uploads/2019/11/logo_white.png webadmin2008-04-14 13:03:272016-11-28 13:03:49SuperGen’s MP-470 Sensitizes Prostate and Breast Cancer Cells to Erlotinib

© Astex Pharmaceuticals
All rights reserved

astex

Useful links

  • Home
  • Sitemap
  • Privacy Policy
  • Terms of Use
  • Legal

Member of the Otsuka Group

Astex Drug Candidates to be Presented at the 2008 AACR Annual MeetingData Show SuperGen’s MP-470 is Safe in Humans
Scroll to top